Full Press Release Details
MARLBOROUGH, Mass. , Oct. 7, 2015 /PRNewswire/ -- Boston Scientific (NYSE: BSX ) today announced key data presentations spanning its broad interventional cardiology, structural heart and peripheral interventions portfolios to be shared at the 27th Transcatheter Cardiovascular Therapeutics (TCT) meeting, the annual scientific symposium of the Cardiovascular Research Foundation, to be held in San Francisco October 11-15 .
Scheduled abstracts will evaluate Boston Scientific technologies for treating patients with a range of cardiovascular diseases, and explore topics including:
Earlier this week, the company received FDA approval of the SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System (BP-DES) for the treatment of patients with coronary artery disease (CAD). The commercialization of the first and only BP-DES in the U.S. reinforces the depth and breadth of the Boston Scientific innovative cardiology portfolio.
"The recently approved and first-to-market WATCHMAN Device and SYNERGY Stent are opening doors for cardiologists to treat patients with non-valvular atrial fibrillation and coronary artery disease in new and innovative ways," said Keith Dawkins , M.D., global chief medical officer, Boston Scientific. "In addition to exploring these prevalent health conditions at TCT, we will also share data crucial to the advancement of device-related treatment for patients suffering from aortic valve disease and peripheral arterial disease."
ABSTRACTS OF INTEREST (listed chronologically within product categories)
Coronary Stents
WATCHMAN Device
Structural Heart
Peripheral Interventions
All programs are listed in Pacific Daylight Time and will take place at the Moscone Convention Center unless otherwise noted. For additional product information, visit Boston Scientific at booth #1225.
Lotus is an investigational device and not available for sale in the U.S.
About Boston Scientific Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook .
CONTACTS Media: Trish Backes Boston Scientific Corporation 651-582-5887 (office) [email protected]
Investors: Susie Lisa , CFA Boston Scientific Corporation (508) 683-5565 (office) [email protected]
SOURCE Boston Scientific Corporation